News NICE backs changes to NHS' diabetes care pathway New guidance from NICE on type 2 diabetes management will shake up NHS treatment, with wider use of both SGLT2 inhibitors and GLP-1 agonists.
News Novo Nordisk's CagriSema tops Ozempic in diabetes trial Novo Nordisk is considering filing CagriSema for diabetes, in addition to obesity, after it outperformed Ozempic in a head-to-head study.
News AZ deepens Chinese ties, signs $18.5bn CSPC obesity deal AstraZeneca deepens ties with China, pledging $15bn in investment and signing a big $18.5bn alliance with CSPC Pharma for obesity and diabetes drugs.
News Call goes out for type 1 diabetes screening in UK A finger-prick screening programme for type 1 diabetes should roll out in the UK, say researchers, given a disease-modifying drug is now available.
News JPM: Novo Nordisk CEO gives insight into new strategy Novo Nordisk CEO Mike Doustdar covers oral Wegovy, DTC sales channels, and an under-appreciated obesity pipeline in a wide-ranging presentation.
News Sanofi seeks use of type 1 diabetes drug in younger kids Sanofi could be months away from wider US approval for Tzield, its drug for delaying the progression of type 1 diabetes, in children as young as one.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.